Specialty Pharmacy

PTX-252 is a novel molecular drug designed to increase cancer cells' sensitivity to chemotherapy in the treatment of acute myeloid leukemia.

It’s essential that health care providers across the patient journey demystify the costs of treatment and provide solutions to overcome the financial barriers.

In 2024, Pharmacy Practice in Focus: Health Systems welcomes the launch of the peer-review process, with this issue containing our first peer-reviewed paper.

Biosimilars are proven to be highly similar to the original products with no clinical meaningful differences.

BrainSee creates a new standard for progression prediction in Alzheimer disease, marking a step forward in brain health management with non-invasive screening.

The results also indicated that stress and blood sugar levels were higher among women who had a college degree and women with a higher income.

According to the authors, the findings may have broad implications for understanding recombination and viral evolution within various organisms.

We owe it to our seniors to listen to their needs and ensure pharmacists have the support they need to continue to play a vital role in our communities as frontline providers of essential health care.

The update includes a recommended triple therapy with belimumab as a first line treatment for class III or IV lupus nephritis following the approvals of belimumab and voclosporin.

Variations and conditions included in existing state bills, however, limit the effectiveness of this approach.

Investigators also found that those with HIV were more likely to be readmitted to the hospital within 30 days of cardiac surgery.

Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.

From newsworthy moments to groundbreaking research, these were the most-read specialty pharmacy-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most watched videos on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

Investigators also found that the results demonstrated lower death and hospitalization rates for those with advanced heart failure treated with cell therapy.

Collaboration and knowledge sharing amongst rare disease researchers can be difficult, as these researchers are often spread out throughout the world.

This FDA approval represents the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

The study authors note that increasing education, implementing online services, and removing stigma can help improve the uptake of PrEP in this population.

Three classes of drugs could be 2 to 5 times more effective than ibuprofen for the treatment of migraine attacks, according to results of a study.

The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2013 to 19.3% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.

The aim of developing GP40141 as a biosimilar is to help reduce the cost of the drug and make treatment more affordable for those with idiopathic thrombocytopenic purpura, according to investigators.

Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease.

Drug reaction with eosinophilia and systemic symptoms can start as a rash and quickly progress, affecting the internal organs and requiring hospitalization, even resulting in death.

Although social determinants of health (SDOH) have been a major barrier to access of preexposure prophylaxis for those who are at risk of HIV, commercial determinants of health pose a similar barrier.

Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.

The study authors reported that plans in the South had the highest rates of exclusive PAs for either emtricitabine/tenofovir disoproxil fumarate or emtricitabine/tenofovir alafenamide even if the plan covered both, from 2018 to 2020.

Denise Giambalvo, director of Member Engagement & Business Strategy at the Washington Health Alliance and recently led a biosimilars initiative for the coalition, discusses biosimilar influence of pricing for biologic drugs, trends to expect in 2024, and why education on biosimilars are important for patients, pharmacists, prescribers, and more

In the second part of his interview with Pharmacy Times, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed pharmacists’ role in HIV education and management.